A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea
| Status: | Recruiting |
|---|---|
| Conditions: | Insomnia Sleep Studies, Pulmonary, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 1/23/2019 |
| Start Date: | January 8, 2018 |
| End Date: | July 1, 2023 |
| Contact: | Somers_CPL Lab |
| Email: | CPLOSA@mayo.edu |
| Phone: | 507-255-8794 |
Studies show that sleep apnea increases the risk of cardiovascular disease and is associated
with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown
that fat tissue is likely involved in developing cardiovascular disease. The purpose of this
study is to see how sleep apnea changes fat tissue.
with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown
that fat tissue is likely involved in developing cardiovascular disease. The purpose of this
study is to see how sleep apnea changes fat tissue.
In recent years, the contribution of adipose tissue to obesity-related insulin resistance
(IR), diabetes mellitus and cardiovascular disease (CVD) has become clear.In particular,
accumulation of damaged cells in obese and aging adipose tissue has been shown to impair
adipose tissue function and may thus increase CVD risk. Cellular and molecular alterations in
adipose tissue are known to contribute to adipose tissue and systemic insulin resistance,
chronic inflammation, and may lead to higher blood pressure. Importantly, any clinical
consequences of adipose tissue dysfunction would be compounded by the large amount, and
central metabolic role, of adipose tissue in humans. However, there is a gap in our
understanding of the OSA-induced changes in the adipose tissue and its implication for
development of cardiometabolic disorders.
The aim of this study is to examine the cellular and molecular composition of adipose tissue
in obstructive sleep apnea (OSA) subjects in comparison to adipose tissue from healthy
individuals. We hypothesize that adipose tissue from OSA subjects will have a higher
accumulation of markers of cellular damage with positive p16 and γH2AX. These studies will
provide pivotal insights into pathways that may be targeted to reduce cardiometabolic burden
in OSA population.
(IR), diabetes mellitus and cardiovascular disease (CVD) has become clear.In particular,
accumulation of damaged cells in obese and aging adipose tissue has been shown to impair
adipose tissue function and may thus increase CVD risk. Cellular and molecular alterations in
adipose tissue are known to contribute to adipose tissue and systemic insulin resistance,
chronic inflammation, and may lead to higher blood pressure. Importantly, any clinical
consequences of adipose tissue dysfunction would be compounded by the large amount, and
central metabolic role, of adipose tissue in humans. However, there is a gap in our
understanding of the OSA-induced changes in the adipose tissue and its implication for
development of cardiometabolic disorders.
The aim of this study is to examine the cellular and molecular composition of adipose tissue
in obstructive sleep apnea (OSA) subjects in comparison to adipose tissue from healthy
individuals. We hypothesize that adipose tissue from OSA subjects will have a higher
accumulation of markers of cellular damage with positive p16 and γH2AX. These studies will
provide pivotal insights into pathways that may be targeted to reduce cardiometabolic burden
in OSA population.
Inclusion Criteria
- BMI ≤40 kg/m2
- Not a current smoker or tobacco user
- Absence of any chronic medical conditions other than seasonal or environmental
allergies, depression, acid reflux and acne.
- Individuals with untreated hypertension, prehypertension, and dyslipidemia will be
allowed to participate in the study
- On no prescription medications other than those medications used to treat asthma,
seasonal or environmental allergies (such as cetirizine, Fexofenadine, Desloratadine,
Loratadine, etc), depression, acid reflux (such as antacids or proton pump
inhibitors), topical skin treatment medications or shampoos, contraceptive pills, or
intrauterine devices. Other medications may be allowed at the discretion of the study
staff.
- Ability to provide written informed consent
Exclusion Criteria
- Vulnerable study population will be excluded
- Presence of chronic diseases such as diabetes, chronic kidney disease, cancer and
cardiovascular disease
- Pregnancy
- Anemic (hemoglobin <13.5 g/dL for men and <12.0 g/dL for women)
- Use of chronic medications (statins, synthroid, beta-stimulants, anti-inflammatory
drugs)
- Blood or plasma donation during the past 2 months
- Known malignancy such as inflammatory disease, surgery, and trauma.
We found this trial at
1
site
Click here to add this to my saved trials
